ARCHIVES

Phase III Trebananib Trial Fails OS Endpoint In Recurrent Platinum-Resistant Ovarian Cancer

This article is from The Cancer Letter archive.

Vol. 37 No. 11 | November 28, 2014

Download PDF Visit The Full Archive

Related Articles

ASCO Foundation Renamed

February 18, 2011

NCI Cancer Education Program To Open To Innovative Ideas

April 2, 1993

In This Issue: The controversy Over “Cancer Undefeated”

June 6, 1997

Radium-233 Dichloride Increased Overall Survival in Phase III Trial

June 29, 2012

Coalition Opens Web Site To Promote Cancer Trials.

June 15, 2001

Revlimid Shows 91 Percent Response in Non-Hodgkin’s

July 29, 2011